Rebastinib clinical trials
Also written DCC-2036.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses rebastinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses rebastinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsTerminatedPhase 1/2Deciphera Pharmaceuticals, LLCNCT03717415Written as RebastinibHow we know
- A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsTerminatedPhase 1/2Deciphera Pharmaceuticals, LLCNCT03601897Written as RebastinibHow we know
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)CompletedPhase 1Deciphera Pharmaceuticals, LLCNCT00827138Written as DCC-2036How we know
Given beside what is tested · 1 — rebastinib is usual care or a partner of the new treatment
Codes
What other systems call rebastinib · ClinicalTrials.gg INT000961
- MeSH (NLM) C000627803rebastinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 75017Q6I97REBASTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27088522rebastinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152162RebastinibOne source FDA
- DrugBank DB13005One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627803 | rebastinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 75017Q6I97 | REBASTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088522 | rebastinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152162 | Rebastinib | One source FDA |
| DrugBank | DB13005 | — | One source Wikidata |
Also registered as rebastinib tosylate (UNII 042A5NJE6B).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.